ArticleScience translational medicine2023

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc

Stéphanie Braillard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.